Abstract: Disclosed are a system, a method, and storage medium for controlling a hydrogen refueling action of a fuel cell vehicle. The method includes: obtaining a structural design parameter of a hydrogen system of the fuel cell vehicle and a driving data set of the fuel cell vehicle; determining a first hydrogen refueling feature set and a second hydrogen refueling feature set of the fuel cell vehicle; determining whether the fuel cell vehicle is in a high hydrogen consumption state; generating a consumption reduction command and sending the consumption reduction command to a vehicle control unit; and controlling, by the vehicle control unit based on the consumption reduction command, a fuel cell control unit (FCU) to adjust an injection frequency of a hydrogen injector, and controlling a motor control unit (MCU) to set a peak threshold of a stator current to limit a maximum phase current of a motor.

Abstract: A dual-control system for an electric bicycle and a switching method for velocity and torque drive for an electric bicycle are disclosed. A dual-driven algorithm controller provided by the present application receives instructions from an instrument communication signal module, interacts with a bilateral single-direction signal magnetic detection torque sensor to obtain velocity signals or torque signals, and then outputs a corresponding velocity or torque through a field oriented control (FOC) motor control module; and the bilateral single-direction signal magnetic detection torque sensor is configured to convert the twist deformation of a bottom bracket in a pedal of an electric bicycle into electrical signals.

Abstract: The present invention relates to heterocyclic compounds or their pharmaceutically acceptable salts as VAV1 protein degraders. Specifically, the invention relates to compounds of Formula I and their pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing the compounds of the present invention. The compounds of the present invention can be used for the treatment and/or prevention of VAV1-mediated diseases, including autoimmune and inflammatory diseases, and cancers.

Abstract: A method for preparing orelabrutinib and an intermediate compound thereof. Specifically, the present disclosure relates to a method for preparing 6-(1-acryloylpiperidin-4-yl)-2-(phenoxyphenyl)pyridine-3-carboxamide and an intermediate compound thereof. The preparation method features simple route, inexpensive and easily available raw materials, mild conditions, and a high product yield. It can greatly reduce the production cost, is environmentally friendly, and is easily adaptable to industrial-scale production.

Abstract: The present invention relates to bridged bicyclic Compounds A and B or their pharmaceutically acceptable salts thereof as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. The present invention also relates to methods for preparing Compounds A and B or their pharmaceutically acceptable salts thereof. Compounds of the present invention can be used to treat and/or prevent related diseases mediated by BTK or its C481 mutant, especially cancer and autoimmune diseases.

Abstract: Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers.

Abstract: The present invention relates to compounds suitable for inhibiting or regulating the activity of IL-17. The present invention is directed to compounds shown in Formula (I) and their pharmaceutically acceptable salts thereof. The present invention further relates to methods for treating and/or preventing various human diseases, including inflammatory and autoimmune disorders. The present invention also provides methods for preparing the compounds of the present invention.

Abstract: A dual-control system for an electric bicycle and a switching method for velocity and torque drive for an electric bicycle are disclosed. A dual-driven algorithm controller provided by the present application receives instructions from an instrument communication signal module, interacts with a bilateral single-direction signal magnetic detection torque sensor to obtain velocity signals or torque signals, and then outputs a corresponding velocity or torque through a field oriented control (FOC) motor control module; and the bilateral single-direction signal magnetic detection torque sensor is configured to convert the twist deformation of a bottom bracket in a pedal of an electric bicycle into electrical signals.

Abstract: The present invention relates to an amorphous solid dispersion comprises (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide (Compound I) and a pharmaceutically acceptable polymer. The present invention also relates to a pharmaceutical composition comprising the amorphous solid dispersion. The amorphous solid dispersion of the present invention is stable upon storage and provides better solubility and bioavailability when comparing with a crystalline form.

Abstract: Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers.

Abstract: Disclosed are a new indoline-1-carboxamide compound for regulating or inhibiting the activity of vascular endothelial growth factor receptor (VEGFR), a preparation method therefor, and the medical use thereof. Specifically, the present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof, a method for treating and/or preventing VEGFR-mediated related disorders, especially tumors, using the compound or a pharmaceutically acceptable salt thereof, as well as a method for preparing the compound or a pharmaceutically acceptable salt thereof. The present invention also relates to the use of the compound or a pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating and/or preventing VEGFR-mediated related disorders, especially tumors.

Abstract: The present disclosure relates to a device and a method for valuating a heat dissipation capability of a test platform of hydrogen fuel cell system. A plurality of PTC heaters are connected in series or in parallel in a primary or secondary dispersion water loop to simulate the fuel cell system with different heating powers. A rotation speed of water pump and whether a PTC is operated are controlled, thereby implementing steady and dynamic tests, and a test for integrative operating condition, thereby avoiding a real machine test from controlling a plurality of parameters. Compared with the real machine of a fuel cell, it can better test the heat dissipation capability of the fuel cell system. During the operation, the device does not need to be supplied reaction gases to ensure the safety of the test. The primary and secondary dispersion tests can be performed separately or in parallel.

Abstract: The present invention relates to various crystalline forms of (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide. The present invention also relates to pharmaceutical compositions comprising the crystalline forms.

Abstract: The present disclosure relates to a fuel cell technology, and in particular, to a method and a system for analyzing hydrogen refueling action of a fuel cell vehicle based on a big data platform. By extracting a structural design parameter set of a hydrogen system of a fuel cell vehicle and a driving data set of the fuel cell vehicle in a preset time period, and further analyzing the obtained hydrogen refueling action data, it calculates a first hydrogen refueling feature set and a second hydrogen refueling feature set of the fuel cell vehicle and finally obtain hydrogen refueling action features corresponding to driving of the fuel cell vehicle in a preset time period.

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: The present invention relates to processes for preparing 6-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (Compound I) in a large scale of over 1 Kg. The processes provide a good yield and a purity of at least 95% of the final product and provide a controllable and safe reaction.

Abstract: The present invention relates to an amorphous solid dispersion comprises 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (Compound I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer. The present invention also relates to pharmaceutical compositions comprising the amorphous solid dispersion. The amorphous solid dispersion of the present invention is stable upon storage and provides a better dissolution rate and bioavailability when comparing with a crystalline form.

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: The present invention relates to the field of golf hitting data analysis technology and discloses a golf hitting data analyzer, which includes a sensor group, a static golf ball detector, an ultra high speed motion detector, a cascaded high-speed motion target tracker, a hitting parameter calculator, and an output. In the present invention, the advanced image processing capability of the GPU chip is utilized, combined with a color high-definition LED display screen to display hitting data. The hitting data is processed in real-time, discrete flight trajectories are calculated, and the three-dimensional flight trajectory of the golf ball is simulated in animation form, without the need for external simulator software, making it more convenient to carry and use.